Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
Tyrosine kinase inhibitors such as erlotinib are commonly used as a therapeutic agent against cancer due to its relatively low side-effect profile and, at times, greater efficacy. However, erlotinib resistance (ER) in non-small cell lung cancer is being recognized as a major problem. Therefore, unde...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Public Library of Science (PLoS)
2012
|
| Subjects: | |
| Online Access: | https://doaj.org/article/10617858532e444492e98bbf859e0d62 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|